Holders — by stockHoldings — by fund
Foresite Capital Management V, LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001792206
$362.2M
disclosed book value
9
positions
45.8%
largest position share
Positions, as of 2026-06-30
top 9 of 9 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | ALMSALUMIS INC. | 5.9M | $165.9M | 45.8% |
| 2 | CGONCG Oncology, Inc. | 1.1M | $76.7M | 21.2% |
| 3 | IRONDisc Medicine, Inc. | 374,069 | $27.4M | 7.6% |
| 4 | HIMSHims & Hers Health, Inc. | 738,151 | $25.6M | 7.1% |
| 5 | PHVSPharvaris N.V. | 664,142 | $23.0M | 6.3% |
| 6 | EIKNEikon Therapeutics, Inc. | 1.3M | $17.2M | 4.8% |
| 7 | ODTXOdyssey Therapeutics, Inc. | 713,105 | $13.3M | 3.7% |
| 8 | LYELLyell Immunopharma, Inc. | 476,386 | $6.7M | 1.8% |
| 9 | NRIXNurix Therapeutics, Inc. | 265,000 | $6.4M | 1.8% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.